Clinical research report on traditional Chinese patent medicines and traditional Chinese classic famous prescriptions (2022)

Abstract

Objective: The paper is to comprehensively summarize and analyze the basic situation and methodological quality of clinical randomized controlled trials (RCTs) of traditional Chinese patent medicines and traditional Chinese classic famous prescriptions published in 2022, to provide evidence and reasonable suggestions for the advancement of clinical research and the formulation of policies and guidelines.
Methods: The Evidence Database System of clinical evidence-based evaluation of traditional Chinese medicine was searched, and data from China National Knowledge Infrastructure (CNKI), PubMed, and other databases were supplemented. The search duration was from January 1, 2022, to December 31, 2022. RCTs of traditional Chinese patent medicines and traditional Chinese classic famous prescriptions were included as the source of clinical evidence, and published information, sample size, intervention, control measures, treatment course, methodological quality, and key link report were analyzed and evaluated.
Results: A total of 1,464 RCTs of traditional Chinese patent medicines were included, which comprised 667 types of traditional Chinese patent medicines; “traditional Chinese patent medicinesβ+βWestern medicine vs. Western medicine” was the most widely used intervention and control setting, involving 417 RCTs (28.48%). A total of 245 RCTs of traditional Chinese classic famous prescriptions were included, comprising 55 types of traditional Chinese classic famous prescriptions. “Decoctionβ+βconventional treatment vs. conventional treatment” was the most widely used intervention and control setting, with 87 RCTs (35.51%). Published RCTs on traditional Chinese patent medicines and traditional Chinese classic famous prescriptions were limited by the study design and implementation. Most “allocation concealment” and “blinding of patients and personnel” were rated as medium to high risk. There are insufficient reports on key research links such as experimental registration and ethical approval.
Conclusions: The number of RCTs on traditional Chinese patent medicines has decreased in 2022, but there has been a slight improvement in the research quality and impact. There are relatively few studies on traditional Chinese classic famous prescriptions. Measures must be taken to improve clinical trial design, implementation, and reporting. Methodological experts should be invited to provide professional technical guidance on the trial design. In the research implementation process, attention should be paid to quality control, particularly the standardization of the randomized execution.

Keywords

Chinese patent medicine / Evidence-based medicine / Randomized controlled trials / Traditional Chinese classic famous prescriptions

参考文献

[[1]] Wu JR, Ma B.Prescription and Chinese Patent Medicine. Beijing: People’s Health Publishing House; 2013.

[[2]] Jin R, Zhao KJ, Guo GM, et al. Expert consensus on prescription comment of Chinese traditional patent medicine for promoting the rational use of drugs in Beijing. China J Chin Mater Med 2018;43(5):1049-1053.

[[3]] Zhang P, Liu A, Wu L, et al. Overview of famous classical formulas and discussion on its exploitation. Chin J Exp Tradit Med Formulae 2020;26(15):183-194.

[[4]] Li B, Liu SH, Zhang CC, et al. Textual research principles and suggestions on function and indication of ancient classical formulas. China J Chin Mater Med 2021;46(7):1846-1850.

[[5]] Cao MD, Wu R, Wang Z, et al. Varieties, indications and medication characteristics of traditional Chinese patent medicines and simple preparations approved for listing in China. Chin Tradit Pat Med 2018;41(8):1999-2006.

[[6]] Ou Y, Ji ZC, Hu HY, et al. Review of reports of clinical evidence of Chinese patent medicines in 2019-2020. Tianjin J Tradit Chin Med 2022;39(5):616-621.

[[7]] Peng DH, Qiang XY, Hu HY, et al. Clinical evidence analysis report of Chinese patent medicine in 2020. China J Chin Mater Med 2022;47(9):2315-2321.

[[8]] Gan XF, Li GL, Cui YX, et al.Research status of clinical comprehensive evaluation methods of Chinese patent medicine. Chin Arch Tradit Chin Med 2023. Published online October 17. Available from: Research status of clinical comprehensive evaluation methods of Chinese patent medicine. Chin Arch Tradit Chin Med 2023. Published online October 17. Available from: http://kns.cnki.net/kcms/detail/21.1546.R.20231016.0910.016.html.

[[9]] Zhang MY, Yang FW, Li Y, et al. Quality evaluation of randomized controlled clinical trials in Chinese Journal of Integrated Traditional and Western Medicine. Chin J Evid Based Med 2017;17(3):357-363.

[[10]] Zhang JH, Sun X. Evidence-based Chinese Medicine. Shanghai: Shanghai Scientific and Technical Publishers; 2018.

[[11]] Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration; 2011. Available from: https://www.cochrane-handbook.org. Accessed July 5, 2023.

[[12]] Wu QF, Ding HF, Deng W, et al. ROBIS: a new tool to assess risk of bias in systematic reviews. Chin J Evid Based Med 2015;15(12):1454-1457.

[[13]] Chen X, Hao C, Deng W, et al. Effects of the Zishen Yutai pill compared with placebo on live births among women in a fresh embryo transfer cycle: a randomized controlled trial. Obstet Gynecol 2022;139(2):192-201.

[[14]] Yu XF, Zhu XY, Yuan CX, et al. Naoxintong capsule for secondary prevention of ischemic stroke: a multicenter, randomized, and placebo-controlled trial. Chin J Integr Med 2022;28(12):1063-1071.

[[15]] Song XL, Yang XC, Lu N, et al. Multi-center randomized controlled trial of Xinsuning capsule in the treatment of ventricular premature beat with phlegm-heat disturbing Xin syndrome. Chin J Integr Tradit West Med 2022;42(4):438-443.

[[16]] Shi H, Zhou J, Ma C, et al. Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: a subgroup analysis of a phase IV randomized clinical trial. Front Cardiovasc Med 2022;9:1002400.

[[17]] Huang JH, Cai D, Biang JL, et al. Effect of Naoxinqing tablet in the treatment of convalescent stroke: a multicenter randomized, double-blind, control trial. Chin J Integr Tradit West Med 2022;42(7):802-810.

[[18]] Lai X, Dong Z, Wu S, et al. Efficacy and safety of Chinese herbal medicine compared with losartan for mild essential hypertension: a randomized, multicenter, double-blind, noninferiority trial [published correction appears in Circ Cardiovasc Qual Outcomes. 2022 Apr;15(4):e000107]. Circ Cardiovasc Qual Outcomes 2022;15(3):e007923.

[[19]] Lu RR. Effect analysis of Motherwort injection combined with Wujia Biochemical capsule in promoting puerperal uterine involution. Contemp Med Symp 2022;20(2):158-161.

[[20]] Wu SX, Fang QH, Su WQ, et al. Clinical efficacy observation of yingiao qingre tablet. Biomed Transform 2022;3(3):82-92.

[[21]] Rui JM, Zhang SY, Su YJ, et al. Clinical study of Tongmai Yangxin Pills in the treatment of female primary stable microvascular angina. China Med Her 2022;19(13):145-148.

[[22]] Wei P, Liu DX, Xu ZM, et al. Study on the efficacy and safety of Bi Dou Yan oral liquid in the treatment of acute rhinosinusitis in children. Chin J Pract Pediatr 2022;37(5):385-390.

[[23]] Yu Y, Xie XL, Wu J, et al. Efficacy and safety of Shenqu Xiaoshi oral liquid compared with domperidone syrup in children with functional dyspepsia. Front Pharmacol 2022;13:831912.

[[24]] Ma XC, Zhang DW, Wang AZ, et al. Effects of Yangxin Dingji capsule for ventricular premature contractions: a multicenter randomized double-blind controlled trial. Chin J Integr Tradit West Med 2022;42(12):1428-1434.

[[25]] Liang H, Wang O, Cheng Z, et al. Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: a randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial. J Orthop Translat 2022;35:53-61.

[[26]] Drug Evaluation Center of the State Drug Administration. Drug Clinical Trial Registration and Information Disclosure Platform. Available from: http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml. Accessed August 5, 2023.

[[27]] Sheng JZ, Zhang BL. Report on the Development of Traditional Chinese Medicine in 2021. Shanghai: Shanghai Scientific and Technical Publishers; 2022.

[[28]] Wu XL, Qiang XY, Ji ZC, et al. Clinical trials and evaluation of Chinese patent medicine for heart failure. China J Chin Mater Med 2022;47(9):2322-2329.

[[29]] Ji ZC, Qiang XY, Hu HY, et al. Clinical trials and evaluation of Chinese patent medicine for pneumonia. China J Chin Mater Med 2022;47(9):2343-2350.

[[30]] Sheng XD, Chen Z, Ji ZC, et al. Clinical trials and evaluation of Chinese patent medicine for influenza. China J Chin Mater Med 2022;47(9):2338-2342.

[[31]] Feng CN, Hu HY, Ji ZC, et al. Clinical trials and evaluation of Chinese patent medicine for chronic obstructive pulmonary disease. China J Chin Mater Med 2022;47(9):2351-2357.

[[32]] Zhang JH, Li YP, Zhang BL. Evidence-based Chinese medicine: theory and practice. China J Chin Mater Med 2018;43(1):1-7.

[[33]] Junhua Z, Hongcai S, Xiumei G, et al. Methodology and reporting quality of systematic review/meta-analysis of traditional Chinese medicine. J Altern Complement Med 2007;13(8):797-805.

[[34]] Zhang ZG, Wang XH, Zhang QN. Potential bias due to the definition of RCTs for inclusive criteria of systematic reviews published in Chinese journals. Chin J Evid Based Med 2013;13(6):764-767.

[[35]] Wang Z, Pang ZY, Wang CS, et al. Therapeutic effect of Danggui Sini Decoction combined with mecobalaminon diabetic peripheral neuropathy. Chin J Drug Abuse Prev Treat2022;28(7):950-953, 957.

[[36]] Yang F, Li HT. Effect of Shashen Maidong Decoction on the serum inflammatory indexes and immune function in patients with pneumonia. J Changchun Univ Chin Med 2022;38(4):402-405.

[[37]] Wang CC, Deng TM, Wang YH. Effect of Wendan Decoction on lipoprotein phospholipase A2 in patients with acute coronary syndrome after percutaneous coronary intervention. J Guangzhou Univ Tradit Chin Med 2022;39(6):1262-1267.

[[38]] Wang D. Evaluation of the therapeutic effect of Simiao Yongan Tang in acute myocardial infarction. Heilongjiang J Tradit Chin Med 2022;51(3):123-125.

[[39]] Wang DM. Effects of Huangqi Guizhi Wuwu decoction combined with Mecobalamin in treatment of patients with diabetic peripheral neuropathy. Med J Chin People’s Health2022;34(11):91-93, 97.

[[40]] Qiu RJ, Wan SQ, Gang ZY, et al. The value of application and prospect of core outcome set in evidence-based traditional Chinese medicine research. Beijing J Tradit Chin Med 2023;42(5):470-474.

版权

2024 Acupuncture and Herbal Medicine